EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS): A 10‐year report

Benjamin L Handen, Mark Mapstone, Sigan Hartley, Howard Andrews, Brad Christian, Joseph H Lee, Dana Tudorascu, Christy Hom, Beau M Ances, Shahid Zaman, Sharon Krinsky-McHale, Adam M Brickman und 14 weitere

Alzheimer's & Dementia · 2025-05 · 21 (5)

DOI: 10.1002/alz.70294 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 15.05.2025. Verfasst von Benjamin L Handen und 25 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh, Department of Psychiatry, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Down Syndrome, Biomarkers, Alzheimer Disease. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCATS NIH HHS, NIA NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Virtually all adults with Down syndrome (DS) will accumulate the neuropathologies associated with Alzheimer's disease (AD) by age 40, with the majority having a clinical dementia diagnosis by their middle 50s. METHODS This paper complements a 2020 publication describing the Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS) methodology by highlighting protocol changes since initial funding in 2015. It describes available clinical, neuropsychological, neuroimaging, and biofluid data and bio‐specimen repository. Ten years of accomplishments are summarized. RESULTS Over 500 adults with DS and 59 sibling controls have been enrolled since 2015 with nearly 800 follow‐up visits. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted; multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. DISCUSSION ABC‐DS is the largest U.S.‐based, multi‐site (including the United Kingdom and Puerto Rico), longitudinal biomarker initiative to target adults with DS at risk for AD. Highlights The Alzheimer's Biomarker Consortium—Down Syndrome (ABC‐DS) is entering its 10th year. Over 500 adults with Down syndrome (DS) and 59 sibling controls have been enrolled. More than 900 magnetic resonance imaging (MRI), 800 amyloid positron emission tomography (PET), and 600 tau PET scans have been conducted. Multiple omics data have been generated using over 1100 blood and 100 cerebrospinal fluid (CSF) samples. It is positioned to continue to make substantial contributions to the DS field.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Down SyndromeBiomarkersAlzheimer DiseaseHumansPositron-Emission TomographyMagnetic Resonance ImagingMaletau ProteinsFemaleAdultMiddle AgedNeuroimagingBrainLongitudinal Studies

Stichwörter der Autor:innen

ABC‐DSAlzheimer's diseaseDown syndromedementia

Substanzen

Biomarkerstau Proteins

Autor:innen und Institutionen

  • University of Pittsburgh, Department of Psychiatry, Pittsburgh, Pennsylvania, USA.
  • University of California, Irvine, Department of Neurology, Irvine, California, USA.
  • University of Wisconsin Madison, Waisman Center, Madison, Wisconsin, USA.
  • Columbia University Irving Medical Center, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, New York, USA.
  • Columbia University, Vagelos College of Physicians and Surgeons, Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, New York, New York, USA.
  • Irvine, University School of Medicine, of California, Department of Psychiatry and Human Behavior, Orange, California, USA.

Förderung

  • NCATS NIH HHS
  • NIA NIH HHS
  • NICHD NIH HHS
  • National Institute on Aging

Zitieren

APA

Handen, B. L., Mapstone, M., Hartley, S., Andrews, H., Christian, B., Lee, J. H., Tudorascu, D., Hom, C., Ances, B. M., Zaman, S., Krinsky-McHale, S., Brickman, A. M., Rosas, H. D., Cohen, A., Petersen, M., O'Bryant, S., Harp, J. P., Schmitt, F., Ptomey, L., …, & Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS) (2025). The Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS): A 10‐year report. Alzheimer's & Dementia, 21(5). https://doi.org/10.1002/alz.70294

Vancouver

Handen BL, Mapstone M, Hartley S, Andrews H, Christian B, Lee JH, et al. The Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS): A 10‐year report. Alzheimer's & Dementia. 2025;21(5). doi:10.1002/alz.70294

BibTeX
@article{Handen2025,
  author = {Handen, Benjamin L and Mapstone, Mark and Hartley, Sigan and Andrews, Howard and Christian, Brad and Lee, Joseph H and Tudorascu, Dana and Hom, Christy and Ances, Beau M and Zaman, Shahid and Krinsky-McHale, Sharon and Brickman, Adam M and Rosas, H Diana and Cohen, Annie and Petersen, Melissa and O'Bryant, Sid and Harp, Jordan P and Schmitt, Frederick and Ptomey, Lauren and Burns, Jeffrey and Lott, Ira T and Lai, Florence and Silverman, Wayne and Laymon, Charles and Head, Elizabeth and Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS), Alzheimer's Biomarker Consortium – Down Syndrome (ABC‐DS)},
  title = {The Alzheimer's Biomarker Consortium–Down Syndrome (ABC‐DS): A 10‐year report},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {5},
  doi = {10.1002/alz.70294}
}
Kostenlos starten →